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Cannabinoids As Potential Treatment
for Chemotherapy-Induced Nausea
and Vomiting
Erin M. Rock and Linda A. Parker *
Department of Psychology and Collaborative Neuroscience Graduate Program, University of Guelph, Guelph, ON, Canada
Despite the advent of classic anti-emetics, chemotherapy-induced nausea is
still problematic, with vomiting being somewhat better managed in the clinic.
If post-treatment nausea and vomiting are not properly controlled, anticipatory
nausea—a conditioned response to the contextual cues associated with illness-inducing
chemotherapy—can develop. Once it develops, anticipatory nausea is refractive to
current anti-emetics, highlighting the need for alternative treatment options. One of
the first documented medicinal uses of 9 91 -tetrahydrocannabinol (1 -THC) was for the
treatment of chemotherapy-induced nausea and vomiting (CINV), and recent evidence
is accumulating to suggest a role for the endocannabinoid system in modulating
CINV. Here, we review studies assessing the therapeutic potential of cannabinoids and
manipulations of the endocannabinoid system in human patients and pre-clinical animal
models of nausea and vomiting.
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INTRODUCTION
Cannabis sativa has been used as a medicine for centuries (see Hanus and Mechoulam, 2005;
Iversen, 2008). It was not until the 1970’s that oncologists demonstrated that smoked cannabis
attenuated chemotherapy-induced nausea and vomiting (CINV). Few clinical trials have compared
the efficacy of cannabis-based medicines with the currently recommended anti-emetic regimen, or
as an adjunct to this treatment. We review findings on the potential of exogenous cannabinoids and
manipulations of the endogenous cannabinoid system to reduce acute and anticipatory CINV.
CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV)
Chemotherapy patients experience acute nausea and vomiting (occurring up to 24 h
post-treatment; Fiore and Gralla, 1984). If improperly managed, this post-treatment CINV can
lead to anticipatory nausea and vomiting; a conditioned nausea response upon re-exposure to the
chemotherapy clinic (Morrow, 1982). Current guidelines to manage highly emetogenic acute CINV
recommend a three-drug regimen of the 5-hydroxytryptamine 3 (5-HT3) receptor antagonist
(such as ondansetron), along with dexamethasone, and a neurokinin 1 (NK1) receptor antagonist
(such as aprepitant) before beginning chemotherapy (Roila et al., 2010). Even with this standard
treatment acute nausea is still problematic (no acute nausea reported in 66% of patients; Kim et al.,
2015). None of these treatments are effective in reducing anticipatory nausea (e.g., Roscoe et al.,
2000), with sedating benzodiazepines currently prescribed (Razavi et al., 1993; Malik et al., 1995).
Therefore, nausea (acute and anticipatory) continues to be problematic.
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CANNABINOIDS IN HUMAN CINV
Because current treatments cannot properly manage CINV,
alternatives including constituents of the cannabis plant and
modulation of the endogenous cannabinoid system, have been
investigated.
Effect of 19-THC and 19-THC-Like
Synthetics
One of the few recognized medicinal effects of the cannabis
plant is the control of CINV, by 19-THC, the psychoactive
compound in cannabis (Gaoni and Mechoulam, 1964). Synthetic
19-THC is available for treatment of CINV in capsule form
as dronabinol (Marinol R©), or nabilone (Cesamet R©). Each of
these compounds acts as a partial agonist of the cannabinoid
1 (CB1) and cannabinoid 2 (CB2) receptors. In comparison
to placebo or the dopamine 2 (D2) receptor antagonists (anti-
emetics which predated the 5-HT3 receptor antagonists), 1
9-
THC or 19-THC-like synthetics are more effective in reducing
acute CINV (Sallan et al., 1975; Chang et al., 1979; Ekert
et al., 1979; Frytak et al., 1979; Herman et al., 1979; Kluin-
Neleman et al., 1979; Orr et al., 1980; Steele et al., 1980; Einhorn
et al., 1981; Orr and McKernan, 1981; Johansson et al., 1982;
Jones et al., 1982; Levitt, 1982; Wada et al., 1982; Ahmedzai
et al., 1983; Niamatali et al., 1984; Niiranen and Mattson,
1985; Dalzell et al., 1986; Niederle et al., 1986; Pomeroy et al.,
1986; Chan et al., 1987; McCabe et al., 1988; Lane et al.,
1990).
The only published clinical trial assessing the effect of
dronabinol on anticipatory nausea showed that dronabinol
was ineffective, although most patients were receiving highly
emetogenic chemotherapy regimens (Lane et al., 1991).
Therefore, dronabinol may be effective in reducing anticipatory
nausea developing from less emetogenic chemotherapy
regimens.
PRE-CLINICAL ANIMAL MODELS OF
VOMITING
Since rats and mice cannot vomit, species capable of vomiting
are used in emesis research. Suncus murinus (house musk
shrew) or Cryptotis parva (least shrew) vomit to toxins such
as nicotine (Matsuki et al., 1988, 1990; Torii et al., 1991;
Nakayama et al., 2005; Parker et al., 2009; Rock et al., 2012),
the chemotherapeutic agent cisplatin (Matsuki et al., 1988,
1990; Torii et al., 1991; Darmani, 1998, 2001b; Sam et al.,
2003; Lau et al., 2005; Parker et al., 2009; Ray et al., 2009;
Rock et al., 2012), or lithium chloride (LiCl; e.g., Parker et al.,
2004). Ferrets also vomit following cisplatin or morphine 6
glucuronide (M6G; Van Sickle et al., 2001, 2003; Sharkey
et al., 2007). These species have therefore been used to
study emesis. Please refer to Table 1 for details regarding
the findings of exogenous cannabinoids and manipulations of
the endogenous cannabinoid system on vomiting in animal
models.
Effect of 19-THC, Tetrahydrocannabinolic
Acid (THCA), and 19-THC-Like Synthetics
on Vomiting
In the least shrew, CB1 receptor agonists such as 1
9-THC
(20mg/kg, i.p.) reduced vomiting induced by the CB1 receptor
antagonist/inverse agonist, SR141716 (20mg/kg, intraperitoneal,
i.p.; Darmani, 2001a). As well, 19-THC (20mg/kg, i.p.) reduced
cisplatin-induced vomiting, and this effect was reversed by
SR141716 [10mg/kg, subcutaneous (s.c.) or 2mg/kg, i.p.] in
the least shrew (Darmani, 2001b; Ray et al., 2009; Wang
et al., 2009). In the house musk shrew, 19-THC (2.5–20mg/kg,
i.p.) also reduced LiCl- and cisplatin-induced vomiting, these
effects were blocked by SR141716 (2.5mg/kg, i.p.) (Kwiatkowska
et al., 2004; Parker et al., 2004). In ferrets, 19-THC (0.5,
1mg/kg, i.p.) reduced cisplatin-, or M6G-induced vomiting,
these effects were blocked by SR141716 (5mg/kg, i.p.; Van
Sickle et al., 2003) or AM251 (5mg/kg, i.p.; Van Sickle et al.,
2001). In addition, 19-THC’s precursor tetrahydrocannabinolic
acid (THCA), present in fresh cannabis and decarboxylated
upon heating or drying of the plant, (0.05, 0.5mg/kg, i.p.)
reduced LiCl-induced vomiting, an effect reversed by SR141716
(2.5mg/kg, i.p.; Rock et al., 2013). These results complement
human findings that 19-THC is anti-emetic, exerting its effect
via the CB1 receptor.
Effect of Cannabidiol (CBD) and
Cannabidiolic Acid (CBDA) on Vomiting
For another non-psychoactive cannabinoid, cannabidiol (CBD)
low doses (5, 10mg/kg, i.p) reduced, but high doses (20–
40mg/kg, i.p.) potentiated LiCl-, nicotine-, and cisplatin-induced
vomiting in house musk shrews (Kwiatkowska et al., 2004; Parker
et al., 2004). Suppression of vomiting by CBD at low doses (5,
10mg/kg, s.c.) was blocked by a 5-hydroxytryptamine 1A (5-
HT1A) receptor antagonist (Rock et al., 2012). CBD’s precursor
cannabidiolic acid (CBDA), is decarboxylated when the fresh
cannabis plant is heated or dried. In house musk shrews, CBDA
(0.1, 0.5mg/kg, i.p.) reduced LiCl-, and cisplatin-induced emesis
(Bolognini et al., 2013). These findings suggest that CBD and
CBDA are anti-emetic in a dose-dependent manner, with CBDA
being more potent.
Effect of Anandamide (AEA) and FAAH
Inhibition on Vomiting
The endogenous cannabinoid, anandamide (AEA), produced
and released on-demand, is rapidly degraded by fatty
acid amide hydrolase (FAAH). As well, FAAH degrades
other fatty acids including oleoylethanolamide (OEA) and
palmitoylethanolamine (PEA), which act on peroxisome
proliferator-activated receptor alpha (PPARα), instead of
CB1 or CB2 receptors. Interestingly, Venkatesan et al. (2016)
reported increased levels of serum OEA and PEA (with a
trend toward increased AEA and 2-AG) while patients were
experiencing cyclic vomiting. On the other hand, no differences
in plasma AEA, OEA or PEA were detected in pregnant women
experiencing hyperemesis gravidarum—severe nausea and
vomiting (Gebeh et al., 2014).
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TABLE 1 | Effect of exogenous cannabinoids and manipulations of the endogenous cannabinoid system on vomiting in animal models.
Compound Species Dose Emetogenic
agent
Effect on
emesis
Receptor
mediation
References
1
9-THC, THCA, AND 19-THC-LIKE SYNTHETICS
19-THC Least shrew 20mg/kg, i.p. SR141716 Reduced CB1 Darmani, 2001a
0.25, 0.5, 1, 2.5, 5,
10mg/kg, i.p.
Cisplatin Reduced Darmani, 2001b; Ray et al.,
2009; Wang et al., 2009
5, 10mg/kg, i.p. D2/D3 receptor
agonists
Reduced Darmani and Crim, 2005
19-THC +
tropisetron
Least shrew 0.25, 0.5mg/kg, i.p. Cisplatin Enhanced
reduction
Not evaluated Wang et al., 2009
CP 55, 940 Least shrew 1mg/kg, i.p. SR141716 Reduced CB1 Darmani, 2001a
WIN 55, 212-2 Least shrew 10mg/kg, i.p. SR141716 Reduced CB1 Darmani, 2001a
19-THC House Musk
Shrew
3–20mg/kg, i.p. LiCl Reduced CB1 Parker et al., 2004
2.5, 5, 10mg/kg, i.p. Cisplatin Reduced Not evaluated Kwiatkowska et al., 2004
19-THC +
ondansetron
House Musk
Shrew
1.25mg/kg, i.p. Cisplatin Enhanced
reduction
Not evaluated Kwiatkowska et al., 2004
19-THC Ferret 0.5, 1mg/kg, i.p. Cisplatin Reduced CB1 Van Sickle et al., 2003
1mg/kg, i.p. M6G Reduced Van Sickle et al., 2001
THCA House musk
shrew
0.05, 0.5mg/kg, i.p LiCl Reduced CB1 Rock et al., 2013
Nabilone Dog 0.1mg/kg, i.v. Cisplatin No effect Not evaluated Gylys et al., 1979
Cat 0.1mg/kg, i.v. Apomorphine,
deslanoside
Reduced Not evaluated London et al., 1979
2.7× 10−7 mole/kg, i.v. Cisplatin McCarthy and Borison,
1981
CBD AND CBDA
CBD House musk
shrew
5, 10mg/kg, i.p. or 5,
10mg/kg, s.c.
LiCl, nicotine,
cisplatin
Reduced 5-HT1A Kwiatkowska et al., 2004;
Parker et al., 2004; Rock
et al., 2012
CBD House musk
shrew
25, 40mg/kg, i.p. LiCl, cisplatin Increased Not evaluated Kwiatkowska et al., 2004;
Parker et al., 2004
CBD + THC House musk
shrew
CBD (2.5mg/kg, i.p.), THC
(1mg/kg, i.p.)
LiCl Enhanced
reduction
Not evaluated Rock and Parker, 2015
CBDA House musk
shrew
0.1, 0.5mg/kg, i.p. LiCl, cisplatin Reduced Not evaluated Bolognini et al., 2013
CBDA + THC House musk
shrew
CBDA (0.05mg/kg, i.p.),
THC (1mg/kg, i.p.)
LiCl Enhanced
reduction
Not evaluated Rock and Parker, 2015
AEA AND FAAH INHIBITION
AEA Ferret 1, 2mg/kg, i.p. M6G Reduced CB1
TRPV1
Van Sickle et al., 2005;
Sharkey et al., 2007
URB597 Ferret 3, 5mg/kg, i.p. M6G Reduced TRPV1 or CB1 Van Sickle et al., 2005;
Sharkey et al., 2007
(Continued)
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TABLE 1 | Continued
Compound Species Dose Emetogenic
agent
Effect on
emesis
Receptor
mediation
References
URB597 House Musk
Shrew
0.9mg/kg, i.p. Cisplatin, nicotine Reduced CB1 Parker et al., 2009
AA-5-HT Least shrew 10mg/kg, i.p. Itself Produced Not evaluated Darmani et al., 2005
URB597 20mg/kg, i.p.
AA-5-HT 2.5, 5mg/kg Cisplatin No effect Not evaluated Darmani et al., 2005
URB597 5, 10mg/kg, i.p.
2-AG AND MAGL INHIBITION
2-AG Least shrew 2.5, 5, 10mg/kg, i.p. Itself Produced CB1 Darmani, 2001c
2-AG House musk
shrew
2, 5mg/kg, i.p. LiCl Reduced Non-CB1 Sticht et al., 2013
JZL184 House musk
shrew
16, 40mg/kg, i.p. LiCl Reduced CB1 Sticht et al., 2013
MJN110 10, 20mg/kg, i.p. CB1 Parker et al., 2015
2-AG Ferret 1, 2mg/kg, i.p. M6G Reduced CB1
CB2
TRPV1
Van Sickle et al., 2005;
Sharkey et al., 2007
In animal models, AEA (1, 2mg/kg, i.p.) reduced M6G-
induced emesis in ferrets, an effect blocked by a transient receptor
potential cation channel subfamily V member 1 (TRPV1)
receptor antagonist (Sharkey et al., 2007) or AM251 (5mg/kg,
i.p.; Van Sickle et al., 2005). The FAAH inhibitor, URB597 (3,
5mg/kg, i.p.) also reduced M6G-induced emesis in ferrets, an
effect blocked by AM251 (5mg/kg, i.p.) or a TRPV1 receptor
antagonist (Van Sickle et al., 2005; Sharkey et al., 2007) but a
PPARα antagonist was not evaluated. URB597 (0.9mg/kg, i.p.)
also reduced nicotine-induced vomiting in house musk shrews,
an effect blocked by SR141716 (2.5mg/kg, i.p.; Parker et al.,
2009). These results suggest the anti-emetic effects of AEA and
FAAH inhibition are mediated by activation of the CB1 receptor.
In ferrets, the TRPV1 receptor also plays a role, an effect not yet
been evaluated in house musk shrews.
In comparison, administration of the FAAH inhibitors AA-
5-HT (10mg/kg, i.p.) or URB597 (20mg/kg, i.p.) themselves
induced emesis (Darmani et al., 2005); however 20mg/kg of
URB597 is a much higher dose than is typically given. These
species-dependent effects of AEA in the modulation of emesis are
puzzling, warranting further investigation.
Effect of 2-AG and MAGL Inhibition on
Vomiting
The endogenous cannabinoid 2-Arachidonoylglycerol (2-AG),
produced and released on-demand, is rapidly degraded by
monoacylglycerol lipase (MAGL). In least shrews, 2-AG (2.5,
5, 10mg/kg, i.p.) produced emesis (Darmani, 2001c). Indeed,
in response to cisplatin in least shrews, brain 2-AG levels
increased, while gut 2-AG levels decreased (Darmani et al.,
2005). This is interesting, as Choukèr et al. (2010) reported
lower blood endocannabinoid levels among those experiencing
motion sickness, and higher blood endocannabinoid levels
among those not.
In contrast, in house musk shrews, 2-AG (1–10mg/kg, i.p.)
did not induce emesis. Instead, 2-AG (2, 5mg/kg, i.p.) reduced
LiCl-induced vomiting (Sticht et al., 2013). Furthermore, 2-AG
(1, 2mg/kg, i.p.) reduced M6G-induced emesis in ferrets, effects
blocked by a TRPV1 receptor antagonist (Sharkey et al., 2007)
or AM251 (5mg/kg, i.p.; Van Sickle et al., 2005) or the CB2
receptor antagonist AM630 (5mg/kg, i.p.; Van Sickle et al.,
2005). Although AM630 did not block vomiting produced by
M6G in ferrets, Rock et al. (2016) found that the CB2 receptor
agonist, HU308 (2.5 and 5mg/kg, i.p.) reduced LiCl-induced
vomiting in house musk shrews, an effect that was reversed by
the CB2 receptor antagonist, AM630 (3mg/kg, i.p.). These results
together suggest that CB1, CB2 and TRPV1 receptors play a role
in the emetic response depending on species and emetic agent
employed.
The selective MAGL inhibitor MJN110 (10, 20mg/kg, i.p.)
suppressed LiCl-induced vomiting in house musk shrews; an
effect reversed by SR141716 (2.5mg/kg, i.p.; Parker et al., 2015).
These results suggest CB1 receptor activation for 2-AG’s anti-
emetic effect, but also suggest TRPV1 or CB2 receptor mediation
in ferrets, effects not yet investigated in house musk shrews.
Overall, these species-dependent effects involving 2-AG andAEA
warrant further investigation.
CONDITIONED GAPING RE-CLINICAL
MODELS OF NAUSEA IN RATS
Use of pre-clinical animalmodels has led to a good understanding
of emesis neurobiology (Hornby, 2001), but the brain circuits
mediating nausea are still not well characterized (Andrews and
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Horn, 2006). Such nausea circuitry may be more complex
than that of emesis (see Kenward et al., 2015). Emesis is
a gastrointestinal event controlled by structures within the
brainstem (Hornby, 2001), whereas nausea is thought to require
forebrain activation (Sanger and Andrews, 2006; Horn, 2008;
Holmes et al., 2009). Although the visceral inputs from the
gastrointestinal tract to the brain have been identified (Cechetto
and Saper, 1987), it is unclear how these inputs are processed
in the forebrain to produce nausea, largely due to the lack
of reliable animal models of nausea. Here we describe current
animal models of nausea. For a complete review of these models
please refer to Sharkey et al. (2014).
To evaluate potential anti-nausea compounds, selective
pre-clinical animal models are necessary. One such model
is conditioned gaping in rats. Please refer to Table 2 for
details regarding the effects of exogenous cannabinoids and
manipulations of the endogenous cannabinoid system in rat
models of conditioned gaping.
Acute Nausea-Induced Conditioned
Gaping
Although rats cannot vomit, they display conditioned gaping
reactions to a taste previously paired with an illness-inducing
agent such as LiCl (Grill and Norgren, 1978). Only emetic drugs
produce, and anti-emetic treatments (including cannabinoids)
block conditioned gaping (see Parker, 2014 for review).
Therefore, acute nausea-induced conditioned gaping is a reliable
model of acute nausea in rats.
Contextually Elicited Conditioned Gaping,
A Preclinical Model of Anticipatory Nausea
Rats also display conditioned gaping upon re-exposure to a
nausea-paired context; this model is similar to the development
of anticipatory nausea in humans (Limebeer et al., 2008).
Furthermore, much like with human anticipatory nausea,
a 5-HT3 receptor antagonist does not reduce contextually
elicited conditioned gaping (Limebeer et al., 2006; Rock et al.,
2014). Humans are treated with nonspecific benzodiazepines
for anticipatory nausea, similarly, benzodiazepines reduce
contextually elicited conditioned gaping in rats (Rock et al.,
2014). Therefore, there is face validity for contextually elicited
gaping as a preclinical model of anticipatory nausea.
The Role of the Interoceptive Insular
Cortex in Conditioned Gaping
Because the specific brain region(s) critical for nausea are
still unclear, we are investigating the role of the endogenous
cannabinoid system in nausea using the conditioned gaping
model. One region of interest is the interoceptive insular cortex
(IC), an area involved in the sensation of nausea in humans
(Penfield and Faulk, 1955), as stimulation of the interoceptive
IC (Ostrowsky et al., 2000; Isnard et al., 2004; Catenoix et al.,
2008) and functional neuroimaging studies in humans (Napadow
et al., 2013; Sclocco et al., 2014), pinpoint the interoceptive IC as
a region critical for nausea.
Effect of 19-THC, THCA, and 19-THC-Like
Synthetics on Nausea
Acute nausea
19-THC (0.5, 1, 10mg/kg, i.p.), HU210 (0.001, 0.005mg/kg, i.p.),
and THCA (0.05, 0.5mg/kg, i.p.) reduced acute nausea-induced
conditioned gaping; an effect blocked by SR141716 (2.5mg/kg,
i.p.) (Parker and Mechoulam, 2003; Rock et al., 2013, 2015a).
Anticipatory nausea
19-THC (0.5mg/kg, i.p.) also reduced contextually elicited
conditioned gaping (Limebeer et al., 2006; Rock et al., 2014),
as did THCA (0.05mg/kg, i.p), these effects were blocked by
SR141716 (2.5mg/kg, i.p.; Rock et al., 2013). These results suggest
that CB1 receptor agonism reduces acute and anticipatory nausea
in rats. However, the potential of CB2 receptor, TRPV1 receptor
and PPARα antagonism to reduce the anti-nausea effects of THC
or THCA have not been evaluated.
Effect of CBD and CBDA on Nausea
Acute nausea
CBD (5mg/kg, i.p. or s.c.) or CBDA (0.5µg/kg–0.1mg/kg, i.p.)
reduced acute nausea-induced conditioned gaping (Parker and
Mechoulam, 2003; Rock et al., 2012), these effects were blocked
by a 5-HT1A receptor antagonist (Rock et al., 2012, 2015a;
Bolognini et al., 2013; Rock and Parker, 2013a). When combined
with a low dose of ondansetron (1µg/kg, i.p.), a subthreshold
dose of CBDA (0.1µg/kg, i.p.) enhanced the suppression of
nausea-induced conditioned gaping (Rock and Parker, 2013a).
Anticipatory nausea
CBD (1, 5mg/kg, i.p.) or CBDA (0.001, 0.01, 0.1mg/kg, i.p.)
suppressed contextually elicited gaping in the absence of any
locomotor impairments (Rock et al., 2008, 2014; Bolognini et al.,
2013), these effects were all reversed by a 5-HT1A receptor
antagonist (Bolognini et al., 2013). These results suggest a 5-
HT1A receptor mediated effect for CBD and CBDA in acute
and anticipatory nausea and also a synergistic potential when
combined with other anti-emetic agents.
Effect of AEA and FAAH Inhibition on nausea
Acute nausea
FAAH inhibition (by PF3845, but not URB597) reduces acute
nausea by a PPARα mechanism of action, not a CB1 receptor
mechanism (Rock et al., 2015b). Previous work suggested that
URB597 in combination with AEA also reduced LiCl-induced
aversive responding, but not gaping per se (Cross-Mellor et al.,
2007). The potential of TRPV1 or CB2 receptor antagonists to
reverse the anti-nausea effects of FAAH inhibition has not yet
been evaluated. It is interesting that elevated OEA and PEA occur
in serum of patients when they are experiencing cyclical vomiting
(Venkatesan et al., 2016), suggesting that they may be playing a
homeostatic protective role. Current investigations are underway
to determine if the anti-nausea effects of FAAH inhibition
(possibly by a PPARα mechanism of action) are peripherally or
centrally mediated.
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TABLE 2 | Effect of exogenous cannabinoids and manipulations of the endogenous cannabinoid system on models of acute and anticipatory nausea in
rats.
Compound Dose details Efficacy in acute nausea-induced
gaping and receptor mediation
Efficacy in contextually elicited gaping
and receptor mediation
1
9-THC, THCA, AND 19-THC-LIKE SYNTHETICS
19-THC 0.5, 1, 10mg/kg, i.p. for acute; 0.5mg/kg,
i.p. for anticipatory
Reduced (Parker and Mechoulam,
2003; Rock et al., 2015a)
Reduced (Limebeer et al., 2006; Rock et al.,
2014)
HU210 0.001, 0.005mg/kg, i.p. Reduced, CB1(Parker and
Mechoulam, 2003)
Not evaluated
THCA 0.05, 0.5mg/kg, i.p. for acute; 0.05mg/kg,
i.p. for anticipatory
Reduced (Rock et al., 2013) Reduced, CB1(Rock et al., 2013)
CBD AND CBDA
CBD 5mg/kg, i.p. or s.c. for acute; 1, 5mg/kg, i.p.
for anticipatory
Reduced, 5-HT1A (Parker and
Mechoulam, 2003; Rock et al., 2012)
Reduced (Rock et al., 2008)
CBDA 0.5µg/kg–0.1mg/kg, i.p. for acute; 0.001,
0.01, 0.1mg/kg, i.p. for anticipatory
Reduced, 5-HT1A (Bolognini et al.,
2013; Rock and Parker, 2013a; Rock
et al., 2015a)
Reduced,
5-HT1A
(Bolognini et al., 2013; Rock et al., 2014)
CBDA + 19-THC CBDA (0.01 and 0.1µg/kg) + 19-THC (0.01
and 0.1mg/kg) for acute; CBDA (1.0,
10µg/kg, i.p.) + 19-THC (1.0, 10mg/kg,
i.p.) for anticipatory
Enhanced Reduction (Rock et al.,
2015a)
Reduced (Rock et al., 2015a)
CBDA + THCA CBDA (0.1µg/kg, i.p.) + THCA (5µg/kg, i.p.) Not evaluated Enhanced reduction, 5-HT1A or CB1(Rock
et al., 2014)
CBDA +
ondansetron
CBDA (0.1µg/kg, i.p.) + ondansetron
(1µg/kg, i.p.)
Enhanced Reduction (Rock and
Parker, 2013a)
Not evaluated
CBDA + D2
receptor antagonist
CBDA (0.1µg/kg, i.p.) + D2 antagonist
(0.3mg/kg, s.c.)
Enhanced Reduction (Rock and
Parker, 2013b)
Not evaluated
AEA AND FAAH INHIBITION
AEA 5mg/kg, i.p. No effect (Cross-Mellor et al., 2007) Not evaluated
0.4µg into the IC No effect (Sticht et al., 2015) Not evaluated
AEA + URB597 AEA (0.4µg) + URB597 (0.01µg) into the IC Reduced (Sticht et al., 2015) Not evaluated
URB597 0.3, 10mg/kg, i.p. No effect (Rock et al., 2015b) Reduced, CB1(Rock et al., 2008)
(0.01µg) into the IC No effect (Sticht et al., 2016) Not evaluated
PF3845 10mg/kg, i.p. for acute; 10, 20mg/kg, i.p. for
anticipatory
Reduced, PPARα (Rock et al., 2015b) Reduced, CB1(Rock et al., 2015b)
2µg into the IC No effect (Sticht et al., 2016) No effect (Limebeer et al., 2016)
AM4303 20mg/kg, i.p. Reduced (Parker et al., 2016) Reduced (Parker et al., 2016)
2-AG AND MAGL INHIBITION
2-AG 1.25, 2mg/kg, i.p. for acute Reduced, COX (Sticht et al., 2012) Not evaluated
2-AG + JZL184 JZL184 (40mg/kg, i.p.) + 2-AG (2mg/kg,
i.p.)
Reduced, CB1(Sticht et al., 2012) Not evaluated
MJN110 10, 20mg/kg, i.p. Reduced, CB1(Parker et al., 2015) Reduced, CB1(Parker et al., 2015)
2µg into the IC Reduced, CB1(Sticht et al., 2016) Reduced, CB1(Limebeer et al., 2016)
AM4301 20mg/kg, i.p. Reduced, CB1(Parker et al., 2016) Reduced (Parker et al., 2016)
2µg into the IC Reduced (Parker et al., 2016) Not evaluated
(Continued)
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TABLE 2 | Continued
Compound Dose details Efficacy in acute nausea-induced
gaping and receptor mediation
Efficacy in contextually elicited gaping
and receptor mediation
DUAL FAAH/MAGL INHIBITION
JZL195 10mg/kg, i.p. for anticipatory Not evaluated Reduced, CB1(Limebeer et al., 2014)
10µg into the IC Reduced (Sticht et al., 2016) Not evaluated
AM4302 20mg/kg, i.p. for acute; 5, 10, 20mg/kg, i.p.
for anticipatory
Reduced (Parker et al., 2016) Reduced, CB1 (Parker et al., 2016)
19-THC,19-tetrahydrocannabinol; 5-HT3, 2-AG, 2-Arachidonoylglycerol; 5-hydroxytryptamine 3; AEA, anandamide; CB1,cannabinoid 1; CB2,cannabinoid 2; CBD, cannabidiol; CBDA,
cannabidiolic acid; CINV, chemotherapy-induced nausea and vomiting; COX, cyclooxygenase; D2, dopamine 2; FAAH, fatty acid amide hydrolase; IC, insular cortex; i.p., intraperitoneal;
LiCl, lithium chloride; NK1, neurokinin 1; MAGL, monoacylglycerol lipase; OEA, oleoylethanolamide; PEA, palmitoylethanolamine; PPARα, peroxisome proliferator-activated receptor
alpha; s.c., subcutaneous; THCA, tetrahydrocannabinolic acid; TRPV1, transient receptor potential cation channel subfamily V member 1.
Anticipatory nausea
In the preclinical model of anticipatory nausea, both URB597
(0.3, 10 but not 0.1mg/kg, i.p.) and PF3845 (10 and 20mg/kg,
i.p.) suppressed the expression of previously established
contextually elicited gaping, with both effects blocked by CB1
receptor antagonism, but not PPARα antagonism (Rock et al.,
2008, 2015b). In addition, the selective FAAH inhibitor, AM4303
(20mg/kg, i.p.), also reduced contextually-elicited conditioned
gaping, with an increase in interoceptive IC AEA levels (Parker
et al., 2016). These results suggest that FAAH inhibition may
reduce anticipatory nausea through a CB1 receptor mediated
effect; however, the potential of TRPV1 receptor antagonists
and CB2 receptor agonists to reverse LiCl-induced anticipatory
nausea expression has not yet been evaluated.
Effect of 2-AG and MAGL Inhibition on Nausea
Acute nausea
Exogenous 2-AG (1.25, 2mg/kg, i.p.) suppressed acute nausea-
induced conditioned gaping; this effect was blocked by
cyclooxygenase (COX) inhibition (but not CB1 or CB2
antagonism; Sticht et al., 2012). When combined with the MAGL
inhibitor JZL184 (40mg/kg, i.p.), 2-AG (2mg/kg, i.p.) suppressed
acute nausea. Since this effect was reversed by AM251 (Sticht
et al., 2012), prolonging 2-AG’s duration of action (by MAGL
inhibition) prevents the nausea produced by longer acting LiCl
by acting at the CB1 receptor. In addition, the MAGL inhibitors
MJN110 (10, 20mg/kg, i.p.) or AM4301 (20mg/kg, i.p.) reduced
acute nausea-induced conditioned gaping, both effects were
blocked by SR141716 (1 or 2.5mg/kg, i.p.; Parker et al., 2015,
2016).
Intracranial administration of MAGL inhibitors (MJN110
[2µg] or AM4301 [2µg]), but not FAAH inhibitors (URB597
[0.01µg] or PF3845 [2µg]) into the interoceptive IC reduced
acute nausea-induced conditioned gaping (Parker et al., 2016;
Sticht et al., 2016) by a CB1 receptor mechansim of action (Sticht
et al., 2016). Furthermore, selective increases in interoceptive
IC 2-AG levels were detected following systemic (20mg/kg,
i.p.) or intra-interoceptive IC infusions of MJN110 (2µg; Sticht
et al., 2016). Interestingly, MJN110 (10mg/kg, i.p.) reduced LiCl-
induced increased c-Fos immunoreactivity in the interoceptive
IC (Sticht et al., 2016). Finally, systemic injection of LiCl
selectively elevated 2-AG levels, but not AEA, in the interoceptive
IC. These data suggest that 2-AG acts as an endogenous anti-
nausea compound in the interoceptive IC.
Anticipatory nausea
MJN110 (10, 20mg/kg, i.p.) also reduced contextually-elicited
conditioned gaping (with elevated interoceptive IC 2-AG levels),
an effect blocked by SR141716 (1mg/kg, i.p.; Parker et al.,
2015). Furthermore, intra-interoceptive IC, MJN110 (2µg, but
not PF3845, nor ondansetron) suppressed contextually elicited
conditioned gaping, blocked by CB1 receptor antagonism
(Limebeer et al., 2016). The MAGL inhibitor, AM4301 (10,
20mg/kg, i.p.), also reduced contextually elicited conditioned
gaping, with a selective increase in interoceptive IC 2-AG levels
(Parker et al., 2016). These results suggest 2-AG (but not AEA)
reduces anticipatory nausea in the interoceptive IC, as well as
acute nausea.
Effect of Dual FAAH/MAGL Inhibition on Nausea
Acute nausea
The dual FAAH/MAGL inhibitor AM4302 (20mg/kg, i.p.)
suppressed acute nausea-induced conditioned gaping (Parker
et al., 2016). Intra-interoceptive IC administration of the dual
inhibitor JZL195 (10µg) also suppressed acute nausea-induced
conditioned gaping (Sticht et al., 2016).
Anticipatory nausea
Systemic administration of JZL195 (10mg/kg, i.p.) also
suppressed contextually elicited gaping, an effect blocked by
SR141716 (2.5mg/kg, i.p.; Limebeer et al., 2014). The dual
inhibitor AM4302 (5, 10, 20mg/kg, i.p.) was more effective than
a FAAH (AM4303) or MAGL inhibitor (AM4301) in reducing
contextually elicited gaping, an effect blocked by SR141716
(2.5mg/kg, i.p), with a concomitant increase in 2-AG and AEA
in the interoceptive IC (Parker et al., 2016). Therefore, dual
FAAH/MAGL inhibition may boost the anti-nausea effects of
elevation of 2-AG or AEA on their own for the treatment of
anticipatory nausea.
CONCLUSIONS
Animal models suggest that, in general, 19-THC, THCA,
CBD, and CBDA, and manipulations of the endogenous
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cannabinoid system, have anti-emetic and anti-nausea
properties. However, 2-AG and AEA’s role in emesis is
inconsistent across species. Further investigation is needed
regarding the potential role of TRPV1 receptors in the
anti-nausea effects produced by treatments that elevate
AEA. It is time to take some of the preclinical findings
(in particular CBDA, FAAH, and MAGL inhibition) into
clinical trials for the treatment of acute and anticipatory
nausea.
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